Therapeutic plan model for induction protocol of non-promyelocytic acute myeloid leukemia

Abstract

Propose a treatment plan model for induction protocol of non- promyelocytic acute myeloid leukemia,  focused   on   reducing   the   adverse   events   inherent   to   pharmacotherapy.   An   exploratory   research   using    UpToDate® and Micromedex® databases of drug interactions, incompatibilities and adverse reactions related  to the chemotherapeutic agents. The drugs analyzed were included in the induction protocol for acute myeloid  leukemia and in the Pharmacotherapeutic Guide from a reference University Hospital in onco-hematology.  The data were analyzed in detail from the technical point of view subsidizing the elaboration of a therapeutic  plan  model  with  the  description  of  the  principal  cares  and  precautions  associated  with  the  use  and  ideal   administration time for the drugs. 18 drug-drug interactions was identified and of these 83.3% (n = 15) have the potential for causing some  adverse  effect.  As  the  outstanding  incompatibilities,  two  have  been identified,  both  physical  and  related  to   anthracycline  daunorubicin.  The  most  frequent  adverse  reactions  was  listed  being myelosuppression  with   greater importance attached the use of cytarabine and followed by gastrointestinal effects. Already related to  daunorubicin  stands  out  with  frequency  greater  than  10%  such  as  abnormalities  on  electrocardiogram  and   alopecia.  From  the  information  obtained,  was  formulated  a  therapeutic  plan  model  by  means  of  a  proposal with ideal administration time aiming to minimize the risks identified in the survey. The  clinical  pharmacist  may  signal  through  the  proposed  model  care  and  precautions  of  conduct,   increasing the team safety and promotes enhancing the quality of care provided to patients.